Michael Markmiller was in excruciating pain for years. The 53-year-old couldn’t walk more than 100 meters without his legs going numb or stand up straight without sharp pains going down his legs.

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Bill would require NM university board of regents members to get ethics and financial training Rep. Melanie Stansbury (D-NM), ranking member of the DOGE subcommittee, joins CNN’s Kasie hunt to discuss ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

One of the more concerning things about high blood pressure is that it’s considered a “silent” killer ― most people don’t have ... those in the second stage may “occasionally” notice pain in a ...

Youngkin said "the pain and sorrow this clemency causes the ... "I’m outraged by Biden granting clemency to cop killers, forcing the fallen officer’s child, Crissana, to relive this trauma.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...